Datopotamab Deruxtecan

• A phase 2 study to research the safety and efficacy of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with acti… Not authorised
  2024-512369-14-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending
  2024-512195-35-00 Phase III 9 countries AstraZeneca AB
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 Phase II/III 11 countries Daiichi Sankyo Inc.
• Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing … Recruiting
  2024-518819-19-00 Phase II 2 countries Medical University Of Vienna
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting
  2024-520101-39-00 Phase III 8 countries AstraZeneca AB
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 Phase III 7 countries AstraZeneca AB
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting
  2025-521904-23-00 Phase II 3 countries AstraZeneca AB
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting
  2024-519913-76-00 Phase II 2 countries Queen Mary University Of London
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting
  2023-505077-32-00 Phase III 7 countries AstraZeneca AB
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum… Recruiting
  2023-503675-24-00 Phase III 4 countries AstraZeneca AB
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting
  2023-509883-89-00 Phase III 5 countries AstraZeneca AB
• Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting
  2023-504984-17-00 Phase I (FiH) 2 countries AstraZeneca AB
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 Phase II 7 countries AstraZeneca AB
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended
  2023-505928-59-00 Phase III 9 countries Astrazeneca AB
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended
  2022-500802-16-00 Phase III 13 countries Daiichi Sankyo Inc.
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended
  2023-505552-22-00 Phase III 8 countries Astrazeneca AB
• Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cance… Ended
  2023-505992-54-00 Phase I (Other) 4 countries Astrazeneca AB
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended
  2023-507933-12-00 Phase III 12 countries Daiichi Sankyo Inc.
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended
  2023-509260-25-00 Phase III 7 countries AstraZeneca AB
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended
  2023-509631-37-00 Phase III 7 countries AstraZeneca AB
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended
  2022-502856-29-00 Phase I (FiH) 5 countries AstraZeneca AB
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended
  2023-509865-19-00 Phase III 7 countries Daiichi Sankyo Inc.
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu… Ended
  2023-504624-25-00 Phase II 5 countries AstraZeneca AB
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended
  2024-511646-40-00 Phase I/II 1 country AstraZeneca AB

Showing 1–24 of 26 trials